Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline, and financial outlook amidst the loss of exclusivity for its blockbuster immunosuppressant Stelara (ustekinumab) in the US. The company anticipates operational sales growth of 5% to 6% in 2024 and 3% or more in 2025, excluding its SARS-CoV-2 vaccine. J&J is also targeting a 5% to 7% compound annual growth rate (CAGR) between 2025 and 2030.
The innovative medicine business is projected to expand by 5% to 7% between 2025 and 2030, propelled by over 20 product launches by the end of the period. This includes more than 15 potential blockbusters such as the immunomodulator JNJ-4804, antidepressants Spravato (esketamine), seltorexant, and aticaprant, along with over 10 assets capable of generating over USD 5 billion in revenue, including the immunosuppressant JNJ-2113 and cancer drugs Talvey (talquetamab) and Tecvayli (teclistamab).
J&J’s medical devices unit is expected to mirror this growth rate through 2027, with high-growth markets in interventional cardiovascular, robotics, and digital sectors driving the expansion.- Flcube.com
